A global equity firm well-versed in pharmaceutical investing is betting the ongoing frenzy in weight-loss drug stock has further to run.
Novo Nordisk and Eli Lilly are among top holdings in the A$1.3 billion Capital Group New Perspective Fund, which is beating 94 per cent of peers this year, according to data compiled by Bloomberg. The long-standing fund, which first invested in the two companies long before recent fervour for obesity treatments, claims ...
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: